Aluminum sulfate calcium acetate

U.S. BRAND NAMES — Domeboro® [OTC]; Gordon Boro-Packs [OTC]; Pedi-Boro® [OTC]

PHARMACOLOGIC CATEGORY
Topical Skin Product

DOSING: ADULTS — Dermal inflammation, dermatitis: Topical: Soak affected area in the solution 2-4 times/day for 15-30 minutes or apply wet dressing soaked in the solution for more extended periods; rewet dressing with solution 2-4 times/day every 15-30 minutes

DOSING: ELDERLY — Refer to adult dosing.

DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Powder, for topical solution:
Domeboro®: Aluminum sulfate 1191 mg and calcium acetate 839 mg per packet (12s, 100s)
Gordon Boro-Packs: Aluminum sulfate 49% and calcium acetate 51% per packet (100s)
Pedi-Boro®: Aluminum sulfate 1191 mg and calcium acetate 839 mg per packet (12s, 100s)

DOSAGE FORMS: CONCISE
Powder, for topical solution:
Domeboro® [OTC]: Aluminum sulfate 1191 mg and calcium acetate 839 mg per packet (12s, 100s)
Gordon Boro-Packs: Aluminum sulfate 49% and calcium acetate 51% per packet (100s)
Pedi-Boro® [OTC]: Aluminum sulfate 1191 mg and calcium acetate 839 mg per packet (12s, 100s)

GENERIC EQUIVALENT AVAILABLE — No

ADMINISTRATION — For external use only. Do not occlude dressing to prevent evaporation.

USE — Astringent wet dressing for relief of inflammatory conditions of the skin; reduce weeping that may occur in dermatitis

WARNINGS / PRECAUTIONS
Other warnings/precautions: Appropriate use: For external use only; avoid contact with eyes. Discontinue use if irritation occurs. OTC duration of therapy: Not for OTC use >7 days.

DRUG INTERACTIONS
Bisphosphonate Derivatives: Calcium Salts may decrease the absorption of Bisphosphonate Derivatives. Exceptions: Pamidronate; Zoledronic Acid. Risk D: Consider therapy modification

Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. Risk C: Monitor therapy

CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger). In older patients, flush lines with compatible fluid between administration. Risk D: Consider therapy modification

DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. Risk C: Monitor therapy

Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag. Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours. Risk D: Consider therapy modification

Estramustine: Calcium Salts may decrease the absorption of Estramustine. Risk D: Consider therapy modification

Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Risk D: Consider therapy modification

Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents. Exceptions: Moxifloxacin. Risk D: Consider therapy modification

Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis. Risk C: Monitor therapy

Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Risk D: Consider therapy modification

Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts. Risk D: Consider therapy modification